| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/27/2006 | US7067624 Antimicrobial proteins |
| 06/27/2006 | US7067621 Multifunctional context-activated protides and methods of use |
| 06/27/2006 | US7067620 Antibacterial agents |
| 06/27/2006 | US7067619 Integrin-binding peptides |
| 06/27/2006 | US7067618 reaction product of a peptide (e.g., an insulin or enkephalin) with a lactose or sialyllactose reducing sugar and optionally reacting the product with polyoxyethylene, polyglutamic acid or polyvinylpyrrolidone; peptide is released in response to pH change; improved in vivo durability of targeted drugs |
| 06/27/2006 | US7067525 Compounds useful as modulators of Melanocortin Receptors and pharmaceutical compositions comprising same |
| 06/27/2006 | US7067497 Inhibiting the division of a malignant mammalian cell and for modulating the effects of cellular aging |
| 06/27/2006 | US7067496 Transplanting into dermis, least one hair follicle that has been modified ex vivo to contain nucleic acid molecule to introduce nucleic acid molecule into mammal |
| 06/27/2006 | US7067495 Subcutaneously injecting to cells of melanoma tumor, an antisense nucleic acid molecule containing a sequence that is the complement of nucleotides 15 1698 of SEQ ID NO:1 |
| 06/27/2006 | US7067492 Method of promoting healing of a tympanic membrane perforation |
| 06/27/2006 | US7067491 3,3,3-trifluoro-1-(methylethyl)-2-oxopropyl]carbamoyl}pyrrolidinyl) derivatives; useful for prophylaxis and treatment for various diseases caused by increased elastase activity, such as diseases caused by increased protein degradation by elastase, especially respiratory diseases |
| 06/27/2006 | US7067490 Hepta-, Octa-and nonapeptides having antiangiogenic activity |
| 06/27/2006 | US7067489 Hematopoietic stimulation |
| 06/27/2006 | US7067488 Modified GLP-1 peptides with increased biological potency |
| 06/27/2006 | US7067487 Amino acid sequence having homology with amino acid position 194 to 220 in a pestiviral Erns protein RNase, from 59-88 in a L3 loop of a cytotoxic RNase of a ribosome-inactivating protein, or 187- 223 in respiratory syncytial virus |
| 06/27/2006 | US7067486 Acetylcholinesterase-derived peptides and uses thereof |
| 06/27/2006 | US7067485 IGF-I composition and its use |
| 06/27/2006 | US7067484 AL-1 neurotrophic factor treatments |
| 06/27/2006 | US7067483 Pharmaceutical compositions containing a gycopeptide antibiotic and a cyclodextrin |
| 06/27/2006 | US7067482 Cross-linked glycopeptide-cephalosporin antibiotics |
| 06/27/2006 | US7067481 Glycopeptide group is covalently linked to a pyridinium moiety of a cephalosporin group; reacting a glycopeptide containing (c6.c6.c6.c6.c6.c10n2.c13n2o.c13n2o ring) with a cephalosporin or salt in presence of a diacid |
| 06/27/2006 | US7067480 Compositions and methods of use for anti-inflammatory agents |
| 06/27/2006 | US7067479 Compositions with enhanced antimicrobial efficacy against E. coli |
| 06/27/2006 | US7067477 Canine erythropoietin gene and recombinant protein |
| 06/27/2006 | US7067476 Peptide derivative containing hydroxy or carbonyl groups and a residue of arganine and lysine side chain in which guanidino and amino groups are protected; used for periodontal disease |
| 06/27/2006 | US7067475 Polypeptides; angiogenesis inhibitor; antitumor agents |
| 06/27/2006 | US7067474 A peptide or polypeptide obtained from the armadillo domain of human beta -catenin polypeptide which inhibits the interaction of human beta -catenin polypeptide and a transcription factor or tumor suppressor protein |
| 06/27/2006 | US7067472 Administering an OB-receptor agonist ligand (which is a recombinant human OB protein, also known as leptin) for conferring resistance to endotoxic shock in an animal in need of resistance to endotoxic shock |
| 06/27/2006 | US7067317 Wound healing agent |
| 06/27/2006 | US7067310 Generation plasmid in prokaryotic cell; obtain cell, incubate with nucleotide sequences, transform cell, allow homologouus recombination to occur, recover recombinamt plasmid |
| 06/27/2006 | US7067309 Used for the transfer and expression of exogenous nucleotide sequences in a host cell or organism; gene therapy |
| 06/27/2006 | US7067301 Comprises nucleotide sequences coding prothrombin enzyme for diagnosis, treatment and prevention of nervous system, liver, blood and cancer disorders; wound healing agents |
| 06/27/2006 | US7067294 Catalytic surfaces for active protection from toxins |
| 06/27/2006 | US7067281 Mammalian IAP gene family, primers, probes and detection methods |
| 06/27/2006 | US7067280 Human cartilage glycoprotein |
| 06/27/2006 | US7067273 Comprises amino acid sequences which serve as substrates for a disintegrin and metalloprotease (ADAM) for use in identification of modulator for treatment of asthma |
| 06/27/2006 | US7067271 screening for compounds that inhibit Amyloid-beta production by contacting a segment of a beta -secretase enzyme protein lacking a transmembrane region; amyloid precursor proteins |
| 06/27/2006 | US7067260 Detecting modulators of receptor binding activity; obtain sample containing receptor protein, incubate with modulator, monitor and evaluate protein binding |
| 06/27/2006 | US7067257 For treatment of encephalomyelitis, leukodystrophy, adrenoleukodystrophy, migraines, epilepsy, Alzheimer's/Parkinson's diseases, and neuron diseases |
| 06/27/2006 | US7067256 Ribozyme mediated inactivation of the androgen receptor |
| 06/27/2006 | US7067255 Hereditary hemochromatosis gene |
| 06/27/2006 | US7067254 Detection of inflammatory response in mammals; obtain cells, culture, incubate with test compound, monitor cell response, compare to control, evaluate for inflammatory response |
| 06/27/2006 | US7067156 nutraceuticals comprising powdered mixture of calcium caseinate, whey protein, L-carnitine and arginine |
| 06/27/2006 | US7067152 Multi component moisture triggered controlled release system that imparts long lasting cooling sensation on the target site and/or provides high impact fragrance or flavor burst |
| 06/27/2006 | US7067144 Compositions and methods for systemic inhibition of cartilage degradation |
| 06/27/2006 | US7067139 Administering Product R, a peptide-nucleic acid preparation, to patients having rheumatoid arthritis; analgesics; antiinflammatory, -swelling, -arthritic agents |
| 06/27/2006 | US7067138 Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis |
| 06/27/2006 | US7067137 Method for treating post herpetic neuralgia by peripheral administration of a neurotoxin |
| 06/27/2006 | US7067135 RAP (RNAIII activating protein) polypeptide of amino acid sequence 13 |
| 06/27/2006 | US7067133 Expression vector encoding a fusion protein with segments of a region which binds to an epitope or fragment and fragment or whole proteins that can cross the blood brain barrier |
| 06/27/2006 | US7067132 Binding to muteins; prevent signal transduction; monoclonal antibodies; graft versus host disease; antiarthritic agents; antidiabetic agents; skin disorders; autoimmune disease; inflammatory bowel disorders; anticancer agents |
| 06/27/2006 | US7067129 Receptor specific transepithelial transport in therapeutics |
| 06/27/2006 | US7067128 Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
| 06/27/2006 | US7067127 Amino and nucleotide sequences; isolated, hybrid nucleic acid; purification of enzyme |
| 06/27/2006 | US7067126 Synthase enzymes having chemokine, angiogenic or angiostsatic activity, used for medical diagnosis and prognosis |
| 06/27/2006 | US7067125 Lantibiotic polypeptides; useful as antimicrobials in antibiotic pharmaceutical preparation and as antimicrobial or antiseptic dentifrice |
| 06/27/2006 | US7067124 Protease composition and method for treating a digestive disorder |
| 06/27/2006 | US7067121 Grafting heart tissue; closure of heart defect |
| 06/27/2006 | US7067119 Using polypeptides |
| 06/27/2006 | US7067118 Methods of using mutant flt3-ligand polypeptides to induce cellular expansion |
| 06/27/2006 | US7067117 Compounds and methods to inhibit or augment an inflammatory response |
| 06/27/2006 | US7067112 Peptaibol antibiotics, synthesized from Acremonium tubakii, during fermentation and released into culture medium, containing high content of beta-aminobutyric acid and isovaline |
| 06/27/2006 | US7067109 Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids |
| 06/27/2006 | CA2237224C Synthetic hpv11 virus-like particles |
| 06/27/2006 | CA2124034C Gene coding for a protein regulating aureobasidin sensitivity |
| 06/26/2006 | WO2006065977A2 Antimicrobial peptides and methods of use |
| 06/24/2006 | CA2531258A1 Semi-synthetic platelet gel and method for the preparation thereof |
| 06/22/2006 | WO2006066234A2 Compositions and methods for reducing lung volume |
| 06/22/2006 | WO2006066110A2 Cav2 RELATED COMPOSITIONS AND METHODS |
| 06/22/2006 | WO2006066065A2 Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising this fragment for detecting, preventing, and treating hiv |
| 06/22/2006 | WO2006066063A1 Nanoparticulate tacrolimus formulations |
| 06/22/2006 | WO2006066024A2 Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
| 06/22/2006 | WO2006066020A2 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 06/22/2006 | WO2006065951A2 Sustained delivery formulations of octreotide compounds |
| 06/22/2006 | WO2006065947A1 Method for treatment of hiv infection |
| 06/22/2006 | WO2006065861A2 Therapeutic formulations of keratinocyte growth factor |
| 06/22/2006 | WO2006065582A2 Muteins of fibroblast growth factor 21 |
| 06/22/2006 | WO2006065395A1 Compositions comprising sclareol or derivatives thereof and uses thereof |
| 06/22/2006 | WO2006065075A1 Method to enhance the bone formation activity of bmp by runx2 acetylation |
| 06/22/2006 | WO2006064906A1 Amorphous composition |
| 06/22/2006 | WO2006064381A2 Protein formulation |
| 06/22/2006 | WO2006064376A1 Peptides for treating retrovirus infection |
| 06/22/2006 | WO2006064133A2 Novel multimeric cd40 ligands, method for preparing same and use thereof for preparing drugs |
| 06/22/2006 | WO2006064072A1 Peptides, nucleotide sequences and cnalinker13 cells and applications thereof |
| 06/22/2006 | WO2006064026A1 Treatment of hepatitis c in the asian population with interferon-beta |
| 06/22/2006 | WO2006063865A2 Compositions for enhancing keratinocyte migration and epidermal repair via a receptor containing osmrbeta as a subunit, and applications thereof |
| 06/22/2006 | WO2006063864A2 Compositions for preventing, reducing or treating keratinocyte-mediated inflammation |
| 06/22/2006 | WO2006063837A2 Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder |
| 06/22/2006 | WO2006063752A1 Improved mevalonate kinase |
| 06/22/2006 | WO2006063567A1 Method for determining inflammatory processes, and pharmaceutical compositions for the treatment thereof |
| 06/22/2006 | WO2006063518A1 Multifunctional polypeptides |
| 06/22/2006 | WO2006063470A1 Metabolites of cyclosporin analogs |
| 06/22/2006 | WO2006063465A1 Treatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists |
| 06/22/2006 | WO2006063415A1 Regulation of metalloprotease cleavage of cell surface proteins |
| 06/22/2006 | WO2006063390A1 Osteoprotegerin variant proteins |
| 06/22/2006 | WO2006061414A1 Methods and agents useful in treating conditions characterized by mucus hyperproduction/ hypersecretion |
| 06/22/2006 | WO2006040047A3 Diagnostics and therapeutics for diseases associated with rho/rac-interacting citron kinase (cit) |
| 06/22/2006 | WO2006039164A3 Novel cyclosporin analogues and their pharmaceutical uses |
| 06/22/2006 | WO2006038129A3 Hepatitis c virus replication system |
| 06/22/2006 | WO2006034832A3 Use of igfbp-2 in senescence diseases and for the maintenance of organ functions |